


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Mercy Memorial Hospital</p> <p>2. 718 N Macomb St. Monroe, MI 48162</p>	<p>In accordance with application dated November 14, 2025,</p>	<p>4. Expiration Date: July 31, 2037</p>
	<p>3. License No.: 21-18816-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-14210 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p>



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-18816-01

Docket or Reference No.:
030-14210

Amendment No. 31

CONDITIONS

10. Licensed material shall be used or stored at the licensee's facilities located at:
- A. 718 N Macomb St., Monroe, Michigan, 48162
 - B. 730 N Macomb, Ste. 429, Monroe, Michigan, 48162
11. The Radiation Safety Officer (RSO) for this license is Lisa Helinski, M.S.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
 - B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)

Material and Use

Matthew G. Aagesen, M.D.	10 CFR 35.100,10 CFR 35.200
Jatin Amin, M.D.	10 CFR 35.100,10 CFR 35.200
Zakaria Ismail Assi, M.D.	10 CFR 35.100,10 CFR 35.200
Raluca Avram, M.D.	10 CFR 35.100,10 CFR 35.200
Garett Begeman, M.D.	10 CFR 35.100,10 CFR 35.200
Paul Berlacher, M.D.	10 CFR 35.200
Jacob Bieszczad, M.D.	10 CFR 35.100,10 CFR 35.200
James F. Bingle, M.D.	10 CFR 35.200
Felix Q. Boucher, M.D.	10 CFR 35.100,10 CFR 35.200
David R. Cervantes, M.D.	10 CFR 35.100,10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-18816-01

Docket or Reference No.:
030-14210

Amendment No. 31

Authorized User (M.D.,D.O.,etc.)Material and Use

Amy Culler, M.D.	10 CFR 35.100,10 CFR 35.200
Laura DeBenedetti, M.D.	10 CFR 35.200
Robert DiSalle, M.D.	10 CFR 35.100,10 CFR 35.200
Farhad Ebrahim, M.D.	10 CFR 35.100,10 CFR 35.200
Nathan Egbert, M.D.	10 CFR 35.100,10 CFR 35.200
Mohamed Elamin, M.D.	10 CFR 35.200
Stephen Eldridge, M.D.	10 CFR 35.100,10 CFR 35.200
Haitham M. Elsamaloty, M.D.	10 CFR 35.100,10 CFR 35.200
Carolyn S. Gbur, M.D.	10 CFR 35.200
Murray Howe, M.D., Ph.D.	10 CFR 35.100,10 CFR 35.200
Adil M. Karamali, M.D.	10 CFR 35.200
Vincent Keiser, M.D.	10 CFR 35.100,10 CFR 35.200
Steven Kumar Jindal, M.D.	10 CFR 35.100,10 CFR 35.200
Terrence Lewis, M.D.	10 CFR 35.100,10 CFR 35.200
Mohammed Maaieh, M.D.	10 CFR 35.200
Hazem Malas, D.O.	10 CFR 35.200
Tamara Martin, M.D.	10 CFR 35.100,10 CFR 35.200
Tarek S. Moustafa, M.D.	10 CFR 35.100,10 CFR 35.200
Jonathan Nadaud, M.D.	10 CFR 35.100,10 CFR 35.200
Carson Oostr, M.D.	10 CFR 35.200
Amir J. Pakray, M.D.	10 CFR 35.100,10 CFR 35.200
Thomas Pappas, M.D.	10 CFR 35.200
Parag Parikh, M.D.	10 CFR 35.100,10 CFR 35.200
Yogesh P. Patel, M.D.	10 CFR 35.100,10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-18816-01

Docket or Reference No.:
030-14210

Amendment No. 31

Authorized User (M.D., D.O., etc.)

Timothy Quinn, M.D.

Zachary Rost, M.D.

Jamal K. Saleh, M.D.

Steven K. Shekut, M.D.

Bruce R. Siders, D.O.

Stephen Stoll, M.D.

Michael A. Walsh, M.D.

Thomas T. Win, M.D.

Jonathan Yobbagy, M.D.

Material and Use

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-18816-01

Docket or Reference No.:
030-14210

Amendment No. 31

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

- A. Application dated June 16, 2021 (ML21176A054)
- B. Letter dated July 6, 2022 (ML22188A066)
- C. Letter dated January 9, 2023 (ML23009B621)
- D. Letter dated March 3, 2023 (ML23062A671)
- E. Application dated November 14, 2025 (ML25337A127)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: February 5, 2026

By: _____

Magdalena R. Gryglak
Region 3